MICs of 22 antimicrobial agents for 60 strains of three Aeromonas species were determined by a microdilution method. The newer cephalosporins such as moxalactam, cefotaxime, and cefoperazone, the aminoglycosides, and chloramphenicol, tetracycline, nitrofurantoin, and trimethoprim-sulfamethoxazole inhibited most of the strains studied. Within the genus, A. hydrophila was more resistant than either A. caviae or A. sobria to the antibiotics tested.
Aeromonas hydrophila, a ubiquitous waterborne organism, has been implicated in a variety of clinical infections including gastroenteritis, cellulitis, and bacteremia in immunocompromised or cirrhotic individuals (4) . Although the genus is well-defined, the exact number of distinct species making up the motile Aeromonas group (often referred to as the A. hydrophila complex) remains unknown. Recent numerical taxonomy and DNA-DNA reassociation studies suggest that at least three species of Aeromonas, namely, A. hydrophila, A. sobria, and A. caviae, should be recognized (13, 14) . The relevance of this proposal is supported by further clinical and microbiologic studies showing that all three species can be recovered from human infections (8) . In addition, several studies suggest that the majority of A. hydrophila and A. sobria strains recovered from gastroenteritis are enterotoxigenic (1, 2, 15) . Invasive potential among the three aeromonal species as judged by their frequency of recovery from blood, their 50% lethal dose for mice and fish, and their exoenzymatic activity also appears to differ substantially (3, 5, 9) .
Previous antimicrobial susceptibility studies of Aeromonas were performed with isolates collectively designated A. hydrophila (6, 7, 12) . Since newer taxonomic criteria have enabled the correlation of different Aeromonas species with distinct infectious processes and virulence potential, the species-associated antibiotic susceptibility patterns may serve as important therapeutic and diagnostic guidelines. In this regard we studied the antimicrobial susceptibility of the three Aeromonas species.
Sixty Aeromonas strains of human origin were tested in this study, and their respective sources of isolation are listed in Table 1 . Of these strains, 39 were recovered in the New York City area, 14 were obtained from the gastrointestinal contents of children in Thailand and were kindly provided by P. Echeverria, and 7 from various clinical sources were submitted by T. Overman. Clinical information was available on 19 of the New York City isolates. Three patients (two with Aeromonas bacteremia and one with Aeromonas gastroenteritis) were receiving antimicrobial therapy either simultaneously or just before the isolation of their respective strains. All isolates were recovered in mixed culture with the exception of two bacteremic strains and one isolate re-covered in pure culture from a patient with Aeromonas wound infection. The clinical significance of these 19 isolates was determined by previously defined criteria (8) , and the results were as follows: primary or secondary pathogen (n = 15, 79%), colonization (n = 1, 5%), and undetermined significance (n = 3, 16%). Species of the isolates were determined by a modification of the original criteria of Popoff and Veron as previously described (9) . MICs were determined by a microdilution method in modified Eugon (cation supplementation for aminoglycosides and thymidine phosphorylase supplementation for trimethoprim-sulfamethoxazole) broth (Uniscept MIC Plus; Analytab Products, Plainview, N.Y.) with an inoculum of approximately 106 CFU/ml.
Results of testing 20 isolates of each species against each of 22 antimicrobial agents are listed in Table 2 . Breakpoints for susceptible, intermediate, and resistant categories were determined by tentative NCCLS standards with the susceptible category used in discussing percent susceptible (11) . All Aeromonas spp. studied were susceptible to gentamicin, amikacin, chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, and nitrofurantoin and uniformly resistant to methicillin, erythromycin, clindamycin and vancomycin. For 7 of 60 Aeromonas isolates, the MIC of tobramycin was >8 ,ug/ml. With beta-lactam antibiotics, all three species were resistant to penicillin, ampicillin, and carbenicillin: 50% of all strains tested, however, were susceptible to piperacillin and mezlocillin. The third-generation cephalosporins moxalactam, cefotaxime, and cefoperazone were uniformly active against the 60 isolates, with MICs ranging from 2 to 64 ,ug/ml. Second-generation cephalosporins (cefoxitin and cefamandole) inhibited approximately 50% of the 60 strains tested.
Of the three species tested, A. hydrophila was more resistant to the penicillins and cephalosporins than either A. 
